Drug Development For Rare Diseases – Have We Gone Too Far?

In this provocative Xconomy commentary, Dr. Stewart Lyman, Owner and Manager of Lyman BioPharma Consulting LLC in Seattle, Washington, raises the question of whether BioPharma has shifted their focus too far in the direction of developing therapies for rare and orphan diseases. There are many reasons why BioPharma is currently incentivized to invest in drug development for rare diseases, but Lyman challenges “do we want to encourage work on diseases where effective treatments will provide the greatest benefit to the most people, or the ones that are the “easiest” to get approved and reimbursed?” Click on the link below to read the full thought-provoking commentary and decide for yourself.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail